Phase 1 Study Of Anitocabtagene Autoleucel For The Treatment Of Patients With Relapsed And/Or Refractory Multiple Myeloma: Results From At Least 1-year Follow-up In All Patients

被引：0
作者：
Frigault, Matthew [1 ]
Rosenblatt, Jacalyn [2 ]
Dhakal, Binod [3 ]
Raje, Noopur [1 ]
Cook, Danielle [4 ]
Gaballa, Mahmoud [5 ]
Emmanuel-Alejandro, Estelle [2 ]
Nissen, Danielle [6 ]
Banerjee, Kamalika [7 ]
Rotte, Anand [7 ]
Heery, Christopher [7 ]
Avigan, David [2 ]
Jakubowiak, Andrzej [8 ]
Bishop, Michael [8 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA
[3] Med Coll Wisconsin, Dept Med, BMT & Cellular Therapy Program, Milwaukee, WI 53226 USA
[4] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[7] Arcellx Inc, Redwood City, CA USA
[8] Univ Chicago, Chicago, IL 60637 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA-30
引用
收藏
页码：S19 / S20
页数：2
相关论文
共 50 条
  • [41] Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study
    Lin, Yi
    Martin, Thomas, III
    Cohen, Adam D.
    Jakubowiak, Andrzej
    Jasielec, Jagoda
    Usmani, Saad Z.
    Madduri, Deepu
    Agha, Mounzer
    Stewart, A. Keith
    Singh, Indrajeet
    Zudaire, Enrique
    Yeh, Tzu-Min
    Allred, Alicia J.
    Olyslager, Yunsi
    Banerjee, Arnob
    Goldberg, Jenna D.
    Schecter, Jordan M.
    Jackson, Carolyn C.
    Deraedt, William
    Geng, Dong
    Wu, Xiaoling
    Carrasco, Marlene J.
    Akram, Muhammad
    Hossain, Farah
    Wang, Vickie
    Berdeja, Jesus G.
    Jagannath, Sundar
    BLOOD, 2020, 136
  • [42] RevoLix™ vaporesection of the prostate: initial results of 54 patients with a 1-year follow-up
    Thorsten Bach
    Thomas R. W. Herrmann
    Roman Ganzer
    Martin Burchardt
    Andreas J. Gross
    World Journal of Urology, 2007, 25 : 257 - 262
  • [43] Efficacy and Safety of Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 Subgroup Analysis
    Jakubowiak, Andrzej
    Usmani, Saad Z.
    Berdeja, Jesus G.
    Agha, Mounzer
    Cohen, Adam D.
    Hari, Parameswaran
    Schecter, Jordan M.
    Madduri, Deepu
    Yeh, Tzu-Min
    Olyslager, Yunsi
    Banerjee, Arnob
    Jackson, Carolyn C.
    Allred, Alicia
    Zudaire, Enrique
    Deraedt, William
    Zhou, Changwei
    Geng, Dong
    Pacaud, Lida
    Lin, Yi
    Martin, Thomas
    Jagannath, Sundar
    BLOOD, 2021, 138
  • [44] Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study
    Jagannath, Sundar
    Richter, Joshua
    Dhodapkar, Madhav V.
    Hoffman, James E.
    Lee, Hans C.
    Suvannasankha, Attaya
    Shah, Mansi R.
    Lentzsch, Suzanne
    Zonder, Jeffrey A.
    Baz, Rachid
    Maly, Joseph J.
    Namburi, Swathi
    Wu, Ka Lung
    Pianko, Matthew
    Ye, Jing Christine
    Silbermann, Rebecca
    Min, Chang-Ki
    Vekemans, Marie-Christiane
    Munder, Markus
    Byun, Ja Min
    BLOOD, 2023, 142
  • [45] Predictors of Survival Outcomes in Phase 1 Relapsed or Refractory Multiple Myeloma Patients
    Barbee, Meagan S.
    Nooka, Ajay
    Kaufman, Jonathan L.
    Kim, Sungjin
    Chen, Zhengjia
    Heffner, Leonard T., Jr.
    Lonial, Sagar
    Harvey, R. Donald
    CANCER, 2015, 121 (06) : 853 - 862
  • [46] RevoLix™ vaporesection of the prostate:: initial results of 54 patients with a 1-year follow-up
    Bach, Thorsten
    Herrmann, Thomas R. W.
    Ganzer, Roman
    Burchardt, Martin
    Gross, Andreas J.
    WORLD JOURNAL OF UROLOGY, 2007, 25 (03) : 257 - 262
  • [47] iMMagine-3: A Phase 3, Randomized Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel (Anito- Cel) With Standard of Care in Patients With Relapsed/ Refractory Multiple Myeloma (RRMM)
    Martin, Thomas
    Raje, Noopur
    San-Miguel, Jesus
    Patel, Krina
    McLoughlin, Lucas
    Lui, Christine
    Jackson, Carolyn
    Heery, Christopher
    van de Donk, Niels
    Berdeja, Jesus
    Mateos Manteca, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S70 - S71
  • [48] A PHASE IB STUDY OF THE AKT INHIBITOR AFURESERTIB IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: FINAL RESULTS WITH LONG TERM FOLLOW-UP
    Trudel, S.
    Spencer, A.
    Sutherland, H.
    O'Dwyer, M.
    Huang, S. Y.
    Stewart, A. K.
    Chari, A.
    Rosenzwieg, M.
    Nooka, A.
    Rosenbaum, C.
    Hofmeister, Cc
    Callander, N.
    Bengoudifa, B. R.
    Gadbaw, B.
    Reyes, M.
    Su, F.
    Voorhees, P.
    HAEMATOLOGICA, 2016, 101 : 82 - 82
  • [49] Updated follow-up of patients treated with bortezomib for relapsed multiple myeloma
    Santini, D.
    Vincenzi, B.
    Tonini, G.
    NATURE CLINICAL PRACTICE ONCOLOGY, 2008, 5 (06): : 304 - 305
  • [50] Updated follow-up of patients treated with bortezomib for relapsed multiple myeloma
    Daniele Santini
    Bruno Vincenzi
    Giuseppe Tonini
    Nature Clinical Practice Oncology, 2008, 5 : 304 - 305
12345